Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
| العنوان: | Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison |
|---|---|
| المؤلفون: | K Gandhi, Vibeke Strand, Peter Nash, Brian Porter, Matthias Hunger, Howard Thom, Steffen M Jugl, Chrysostomos Kalyvas, Walter P. Maksymowych, Yusuf Yazici |
| المصدر: | European Journal of Rheumatology |
| بيانات النشر: | AVES Publishing Co., 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | medicine.medical_specialty, matching-adjusted indirect comparison, Population, comparative effectiveness, Logistic regression, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, ankylosing spondylitis, Adalimumab, medicine, education, 030203 arthritis & rheumatology, Ankylosing spondylitis, education.field_of_study, business.industry, secukinumab, 030503 health policy & services, Odds ratio, medicine.disease, Confidence interval, Indirect comparison, Original Article, Secukinumab, 0305 other medical science, business, medicine.drug |
| الوصف: | Objective: Matching-adjusted indirect comparison was used to assess the comparative effectiveness of secukinumab 150 mg and adalimumab 40 mg in biologic-naive patients with ankylosing spondylitis (AS) for up to 1 year.Methods: Pooled individual patient data from the secukinumab arms of MEASURE 1 (NCT01358175) and MEASURE 2 (NCT01649375) trials (n=197) were matched against the ATLAS (NCT00085644) adalimumab population (n=208). Logistic regression analysis was used to determined weights to match for age, sex, Bath AS Functional Index, C-reactive protein levels, and previous tumor necrosis factor inhibitor therapy. Recalculated Assessment of Spon-dyloArthritis International Society (ASAS) 20 and 40 responses at weeks 8, 12, 16, 24, and 52 from MEASURE 1/2 (effective sample size=120) were compared with those of ATLAS. Anchored (placebo-adjusted) comparisons were possible until week 12, and unanchored (non-placebo-adjusted) comparisons were necessary thereafter.Results: For placebo-anchored ASAS 20 and 40 comparisons up to week 12, there were no differences between secukinumab and adalimumab. For unanchored comparisons at week 16, ASAS 20 was higher for secukinumab [odds ratio 1.60 (95% confidence interval, 1.01-2.54); p=0.047]; at week 24, ASAS 20 and 40 were higher for secukinumab [1.76 (1.11-2.79); p=0.017 and 1.79 (1.14-2.82); p=0.012, respectively]; and at week 52, ASAS 40 was higher for secukinumab [1.54 (1.06-2.23); p=0.023] than for adalimumab.Conclusion: There were no differences observed in placebo-adjusted ASAS 20 and 40 responses up to 12 weeks between secukinumab- and adalimumab-treated patients with ankylosing spondylitis. After week 12, secukinumab demonstrated signs of greater improvement in non-placebo-adjusted ASAS 20 and 40 responses than adalimumab. |
| تدمد: | 2148-4279 2147-9720 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4eb329f6ff5b80aa2f8ec9194af8ad4Test https://doi.org/10.5152/eurjrheum.2018.18162Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f4eb329f6ff5b80aa2f8ec9194af8ad4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21484279 21479720 |
|---|